Bio-Techne (TECH) reported adjusted earnings per share (EPS) of 53 cents for the fourth quarter of fiscal 2025, exceeding the Zacks Consensus Estimate by 6%. The figure improved from 49 cents a year ago. For fiscal 2025, the full-year adjusted EPS reached $1.92, which was 1.1% above estimates, reflecting an 8.5% increase from fiscal 2024.
The company registered net sales of $316.9 million in the fourth quarter, up 3.5% year-over-year, and surpassing estimates by 0.48%. Full-year revenues totaled $1.22 billion, a 5.2% increase from the previous year. Despite the positive earnings and revenue reports, shares dipped 1.2% in pre-market trading.
In Q4, revenues from the Protein Sciences segment reached $226.5 million, a 6% year-over-year increase, while the Diagnostics and Spatial Biology segment saw a decrease to $89.7 million. Gross profit fell 2.2% to $198.8 million, with a gross margin of 62.7%, down 371 basis points due to rising sales costs.
